Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wade, one last note about dillution: I didn't get to listen to today's CC for myself yet, but this post on RB said the company said it has no plans to raise capital "at this time":
http://ragingbull.lycos.com/mboard/boards.cgi?board=UGNE&read=7305
Wade - The balance sheet is ugly on the surface and so are the cautionary statements that go with it, but the loans are from the CEO and his family.....and as a matter of personal opinion, I tend to trust their motives in this situation....the loans bear pretty low interest...and they've waived all the default provisions....and I think they probably just plan to pay the loans off when the company can really afford it....but enough of my opinion....here's the facts from the 10Q:
NOTE F – NOTES PAYABLE – STOCKHOLDERS
To satisfy our short-term liquidity needs, Jay Levy, our Chairman of the Board and an officer, Warren Levy and Ronald Levy, each a director and executive officer of Unigene, and another Levy family member, from time to time have made loans to us. We have not made principal and interest payments on certain loans when due. However, the Levys waived all default provisions including additional interest penalties due under these loans through December 31, 2000. Beginning January 1, 2001, interest on loans originated through March 4, 2001 increased an additional 5% per year and is calculated on both past due principal and interest. This additional interest was approximately $229,000 and $634,000, and total interest expense on all Levy loans was approximately $407,000 and $1,117,000 for the three and nine months ended September 30, 2005, respectively. As of September 30, 2005, total accrued interest on all Levy loans was approximately $6,967,000 and the outstanding loans by these individuals to us, classified as short-term debt, totaled $10,553,323. These loans are secured by security interests in our equipment, real property and/or certain of our patents. In October 2005, we repaid an aggregate of $448,000 in principal on these loans.
11
Table of Contents
Outstanding stockholder loans consist of the following at September 30, 2005 and December 31, 2004 (in thousands):
2005
2004
Jay Levy term loans (1)
$ 1,870 $ 1,870
Jay Levy demand loans (2) (3)
8,225 8,225
Warren Levy demand loans (4)
235 235
Ronald Levy demand loans (5)
223 223
10,553 10,553
Accrued interest
6,967 5,850
Total loans and interest due to stockholders
$ 17,520 $ 16,403
(1) Loans from Jay Levy in the aggregate principal amount of $1,870,000 evidenced by term notes that matured January 2002, and bearing interest at the fixed rate of 11% per year. These loans were originally at 6%. These loans are secured by a security interest in all of our equipment and a mortgage on our real property. The terms of the notes required us to make installment payments of principal and interest beginning in October 1999 and ending in January 2002 in an aggregate amount of $72,426 per month. No installment payments have been made to date. Accrued interest on these loans at September 30, 2005 was approximately $1,550,000.
(2) Loans from Jay Levy in the aggregate principal amount of $2,525,000, which are evidenced by demand notes bearing a floating interest rate equal to the Merrill Lynch Margin Loan Rate plus 5.25% (12.60% at September 30, 2005). These loans were originally at the Merrill Lynch Margin Loan Rate plus .25%. These loans are secured by a security interest in our equipment and real property. Accrued interest on these loans at September 30, 2005 was approximately $3,233,000.
(3) Loans from Jay Levy in 2001 and 2002 in the aggregate principal amount of $5,700,000 which are evidenced by demand notes bearing a floating interest rate equal to the Merrill Lynch Margin Loan Rate plus .25%, (7% at September 30, 2005) and are secured by a security interest in certain of our patents. Accrued interest on these loans at September 30, 2005 was approximately $1,375,000. On February 15, 2005, Jay Levy transferred these $5,700,000 of demand notes to the Jaynjean Levy Family Limited Partnership in exchange for partnership units. Warren Levy and Ronald Levy are general partners of that partnership.
(4) Loans from Warren Levy in the aggregate principal amount of $230,000 which are evidenced by demand notes bearing a floating interest rate equal to the Merrill Lynch Margin Loan Rate plus 5.25% (12.60% at September 30, 2005). These loans were originally at the Merrill Lynch Margin Loan Rate plus .25%. These loans plus accrued interest were repaid in full in October 2005. An additional loan in the amount of $5,000 bears interest at the Merrill Lynch Loan Rate plus .25% (7% at September 30, 2005). These loans are secured by a secondary security interest in our equipment and real property. Accrued interest on these loans at September 30, 2005 was approximately $409,000.
(5) Loans from Ronald Levy in the aggregate principal amount of $218,323 which are evidenced by demand notes bearing a floating interest rate equal to the Merrill Lynch Margin Loan Rate plus 5.25% (12.60% at September 30, 2005). These loans were originally at the Merrill Lynch Margin Loan Rate plus .25%. These loans plus accrued interest were repaid in full in October 2005. An additional loan in the amount of $5,000 bears interest at the Merrill Lynch Margin Loan Rate plus .25% (7% at September 30, 2005). These loans are secured by a secondary security interest in our equipment and real property. Accrued interest on these loans at September 30, 2005 was approximately $400,000.
UGNE: This is a good presentation about the company, their products, and their pipeline:
http://www.wsw.com/webcast/rrshq7/ugne/
Of all the "next VPHM" stocks I've seen mentioned on various boards, I think UGNE most resembles that situation of a small company just emerging into profitability as they introduce a new product into a multi-billion market.
Unigene Reports Record Revenue and Operating Profit for Third Quarter
Tuesday November 22, 7:00 am ET
Net Income of $.10 Per Share for Three Months Ended September 30, 2005
FAIRFIELD, N.J.--(BUSINESS WIRE)--Nov. 22, 2005--Unigene Laboratories, Inc. (OTCBB: UGNE - News) announced its financial results for the period ended September 30, 2005.
Revenue for the nine months ended September 30, 2005 was $12,676,000 compared to $6,409,000 for the nine months ended September 30, 2004. Revenue for the three months ended September 30, 2005 was $11,873,000 compared to $5,216,000 for the three months ended September 30, 2004. Revenue for both the three-month and nine-month periods ended September 30, 2005 included Fortical® product sales to Upsher-Smith Laboratories ("USL") representing launch quantities into distribution channels as well as royalties earned from USL sales following the August 16th product launch. Unigene's net income for the nine months ended September 30, 2005 was $2,157,000 or $.03 per share (basic) compared to a net loss of $4,195,000 or ($.05) per share (basic) for the nine months ended September 30, 2004. Net income for the three months ended September 30, 2005 was $7,897,000 or $.10 per share (basic) compared to net income of $932,000 or $.01 per share (basic) for the three months ended September 30, 2004.
"We are very pleased about the acceptance of Fortical in the marketplace to date," commented Dr. Warren Levy, President and CEO of Unigene. "Product sales are in line with Unigene's expectations and the product is now available at most pharmacies throughout the U.S. We believe that Fortical will remain a key revenue driver for Unigene for the near future."
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
About Upsher-Smith
Upsher-Smith Laboratories, Inc. is a fully integrated pharmaceutical company that manufactures and markets prescription pharmaceutical, OTC and cosmetic products. Upsher-Smith is also actively involved in licensing innovative compounds that are in clinical development. For more information about Upsher-Smith Laboratories, Inc., call 800-654-2299 or visit www.upsher-smith.com
>>>While UGNE does have more shares out than VPHM does, I think the market potential for UGNE's Osteoperosis drugs is a bit larger than the market potential for Vancocin.
I'm buying it here with the intentions of keeping it as a long-term hold.
BIPH: After holding for about 2 years, I sold the last of my position a few weeks ago. The company has been long on promises; but short on results. This is making patience wear thin, even the longest of the longs are getting frustrated now:
http://ragingbull.lycos.com/mboard/boards.cgi?board=BIPH&read=77935
I sold about 80% of my position when the long promised BSX licensing agreement was finally announced, which I didn't think met expectations the CEO had created for it. Then I sold the last of my position a few weeks ago when the CEO announced BIPH was going to receive $250k at the beginning of the year from BSX....which I presumed was the annual licensing fee....which doesn't look very substantial relative to their $150M market cap.
Personally, I can't see that stock making a substantial move until BSX actually introduces a product in a multi-billion market that includes BIPH's technology....or BIPH announces the long promised second licensing agreement. If either of those happen, I'll jump right back on board….but I’m a bit more skeptical now with regard to the forward looking statements from the CEO.
Taking those lessons in stride, I feel safer now holding companies that don't talk so much about their intellectual property, like BLLI.....or companies that are actually showing results....like UGNE.
CNCN doesn't fit the profile for this message board, but many others are discussing it on the VM Zipcodechangers board:
http://www.investorshub.com/boards/board.asp?board_id=3294
UGNE: 3.56/3.57. Just reported 0.09 fully-diluted EPS for the last quarter.
Of all the stocks I've seen called "the next VPHM", I think this one stands the best chance at continually delivering improving results like VPHM has:
Unigene Reports Record Revenue and Operating Profit for Third Quarter
Tuesday November 22, 7:00 am ET
Net Income of $.10 Per Share for Three Months Ended September 30, 2005
FAIRFIELD, N.J.--(BUSINESS WIRE)--Nov. 22, 2005--Unigene Laboratories, Inc. (OTCBB: UGNE - News) announced its financial results for the period ended September 30, 2005.
Revenue for the nine months ended September 30, 2005 was $12,676,000 compared to $6,409,000 for the nine months ended September 30, 2004. Revenue for the three months ended September 30, 2005 was $11,873,000 compared to $5,216,000 for the three months ended September 30, 2004. Revenue for both the three-month and nine-month periods ended September 30, 2005 included Fortical® product sales to Upsher-Smith Laboratories ("USL") representing launch quantities into distribution channels as well as royalties earned from USL sales following the August 16th product launch. Unigene's net income for the nine months ended September 30, 2005 was $2,157,000 or $.03 per share (basic) compared to a net loss of $4,195,000 or ($.05) per share (basic) for the nine months ended September 30, 2004. Net income for the three months ended September 30, 2005 was $7,897,000 or $.10 per share (basic) compared to net income of $932,000 or $.01 per share (basic) for the three months ended September 30, 2004.
"We are very pleased about the acceptance of Fortical in the marketplace to date," commented Dr. Warren Levy, President and CEO of Unigene. "Product sales are in line with Unigene's expectations and the product is now available at most pharmacies throughout the U.S. We believe that Fortical will remain a key revenue driver for Unigene for the near future."
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
About Upsher-Smith
Upsher-Smith Laboratories, Inc. is a fully integrated pharmaceutical company that manufactures and markets prescription pharmaceutical, OTC and cosmetic products. Upsher-Smith is also actively involved in licensing innovative compounds that are in clinical development. For more information about Upsher-Smith Laboratories, Inc., call 800-654-2299 or visit www.upsher-smith.com
GENX: Trailing P/E of 3, just reported $0.02 EPS for the quarter and $0.04 for the first nine months:
http://www.sec.gov/Archives/edgar/data/1197380/000120445905000668/genex10qsb.htm
Sure it's a sleeper, but it's also a biotech company in China that I think stands a good chance of awakening some day....especially if this ever gets finalized:
http://www.findarticles.com/p/articles/mi_m0EIN/is_2004_August_18/ai_n6163962
GENX: 0.14/0.23, 17.9M shares out, 30M authorized.
The company just reported $0.02 EPS for the quarter and $0.04 for the first nine months:
http://www.sec.gov/Archives/edgar/data/1197380/000120445905000668/genex10qsb.htm
That gives the company a trailing P/E of less than 3.
With this value comes a potential wild card that is explained in this post on Raging Bull:
http://ragingbull.lycos.com/mboard/boards.cgi?board=AOBO&read=5178
EP, Thanks for your best guess, although I'm not particularly enamored with it since my entry was at $0.125 :) .....maybe I should have asked you yesterday before I bought, lol!
EP, what's your opinion on the CNCN chart?
EZEN: Knowledge is King, knowledge is zen for EZEN :)
Judging from today's action, I don't think the market really understand why the company says it is "cautiously optimistic with regard to the growth opportunities in 2006."
Unfortunately part of being cautious means they don't tell investors what they're optimistic about :) So we're left to figure that out for ourselves......the knowledge I've gathered has me looking to two specific "growth opportunities" I see in 2006:
1.) The most significant growth opportunity I see is when the NGCS pilot project EZEN is currently participating in gets phased in to the DOD NCES program. I saw a presentation that said the NGCS had 5,000 users, where as the NCES will have 50k on the classified netowrk and 500k on the unclassified network. Unfortunately that link went dead...and I haven't been able to find anything that else that quantifies the scope of this project nearly as clearly.....but the following are also some valuable puzzle pieces:
This link is to a power point presentation from the Navy that explains the objectives of the NCES program and mentions EZEN's IWS product on slide #20 & #24:
http://www.spawar.navy.mil/presentations/afcea/200504/day_1_2005_c4isr/session_2/2-1_maj_schneider_u...
The RFI for the NCES went out in September, the vendors have made their submissions, and Ezenia was called for a "one-on-one" session: https://www.ditco.disa.mil/dcop/public/asp/requirement.asp?req_no=COLLABRFISEP05
2.) Also, their third quarter newsletter had a nice article about EZEN signing a joint marketing agreement with Verizon, but I thought the best information in the newsletter was hidden down under the boring title "Ezenia joins CMAS" where it said: The team expects to open new areas of the California State Government to IWS collaboration and Verizon ESG infrastructure in the coming months. Joint meetings have already taken place in Utility Management, Emergency Operations, 911, National Guard, and State Homeland Security.
>> Me, I bought my first EZEN in 4/20/04 for $0.50, but have been averaging up, so I have an average of $1.75 now…..and am still “cautiously optimistic” my position has 10-bagger potential :)
CNCN looking perky here, I grabbed 25k @ $0.125.
babycakes your talk of PFCE is bringing back painful memories. I actually had the foresight to anticipate this recent run and bought some in August, but let some people talk me out of it later that month:
http://www.siliconinvestor.com/readmsg.aspx?msgid=21586763
Sometimes you just got to listen to your own instincts and ignore all the outside chatter.
BIPH, after being a long time supporter, I was disapointed to see the terms of the agreement with BSX....with only a $750k initial licensing fees....so I sold about 80% of my position then in the $2.80s. Then that PR last week that said BIPH will receive another $250k at the begining of the year for the annual licensing fee was another let down to me....and I sold the rest of my position there.
I don't think I'll be buying any BIPH back until I see the long promised second licensing agreement....or see BSX introduce a product that includes BIPH's technology.
I've moved a good postion of those profits to BLLI around its current prices. The market may not see BLLI as sexy as a BIPH because they're just quietly working away. But they're quietly building a strong core dental implant business in a market that is growing 15% a year.....and quietly filing some interesting patent applications that could eventually make them be recognized as a saexy medical device technology company much like a BIPH....or MIVT....if they ever decided to publicize it.
BioLok International Expands National Sales Coverage
Wednesday November 9, 8:01 am ET
DEERFIELD BEACH, Fla.--(BUSINESS WIRE)--Nov. 9, 2005--BioLok International Inc. (OTCBB: BLLI - News), the manufacturer and worldwide distributor of leading-edge dental implant technology, today announced that it has expanded its national sales coverage in the US. The Company added sales managers in Orange County, CA, Atlanta, GA, Denver, CO, and Connecticut.
"Based on our success to date of increasing sales and market share, we are pleased to announce the expansion of our direct sales force in the United States," said Bruce L. Hollander, President of BioLok International. "The new sales managers enable us to broaden our coverage of some of the largest markets, including California and the northeast's tri-state area. In addition, we have now entered for the first time attractive markets in Atlanta and Denver. Our plans for managed growth call for the hiring of additional sales people by the end of this calendar year and next year."
BioLok International Inc. (OTCBB: BLLI - News) is merging cell biology and technology to develop and market products for the dental implant and tissue regeneration markets. The Company is the worldwide manufacturer and distributor of the BioLok Precision Dental Implant System. BioLok offers a superior line of dental implants that incorporate many patented features and are synonymous with quality, fit of components, leading edge technology and design, and ease of use.
With funding from the National Institutes of Health (NIH) and the National Science Foundation (NSF), BioLok's research and development subsidiary, Orthogen, has developed and patented a proprietary laser microgrooving technology which has been assigned to BioLok. Subsequently, BioLok applied the technology for processing the surfaces of dental implants and related medical products to enhance tissue attachment. The product is marketed by BioLok under the trade name Laser-Lok(TM) and is the basis for significant revenue growth and market share gains by the Company. The laser microgrooving technology has potential applications for transcutaneous devices, orthopaedic implants, peripheral nerve repair, bioreactors, cardiovascular and ophthalmic devices. The Company has ongoing research programs with patents pending or issued in each of these areas.
Additional information is available on the Company's Web site at www.biolok.com.
celticherb, you may want to check out the "Tasty Dooshers" board.
I ocassionally play puts going into earnings on what I feel are over-valued stocks....but as you said....it's a gamble....and I generally limit those "bets" to less than 1% of my portfolio.
EZEN: ARCA with 30k on the ask.....could this be the start of one of them pre-earnings shake outs again?
I say dump 'em with a market order ARCA! Cut through those bids like a warm knife through butter......I'll jump all over another shot at one of those 10% price plunges before earnings!
OT: timhyma, IWS collaboration software is actually one of the most sophisticated and secure "internet messaging" systems available, that's why the gov't. loves it. It's being used in all branches of the DOD, as well as the FBI, state department, and other agencies.
But it's proven to be a bit too pricey for most commercial users. If you work outside the DOD or other related secure gov't work, I would be curious to know what industry you work in.
OT: I guess Trey was just pumping, I didn't think they were too exciting.
Trey siad during his gig earlier today that Arcade Fire was a band worth sticking around for.
EZEN: They just released a newsletter on Friday with a bit of new information about their work with Verizon. I don't know if they'll release a PR to investors about this or not? They're not the most talkative company....but them creating the newsletter this year has been a step in the right direction.
https://www.ezenia.com/newsletters/q3_2005.html
Ironically The Flaming Lips are playing war pigs at Vegoose as I post this :)
Hey EP, I posted BIPH here in post #175 on 9/24/2005 when it was trading at $0.81, do I get a gold star? :)
tech, I think you'll have fun with GORX tomorrow. They've got a nice settlement to add to their bottom line tomorrow....and should also have some nice growth in their generic pet meds.
I might jump on in the morning if it doesn't get too crazy, but wish I would have bought it last week before the momentum started....darn!
GL!
BLLI: This stent patent application makes BLLI a potential zip code changer IMO.
Here's some excerpts from the recent patent application of theirs:
Surgical stent having micro-geometric patterned surface
1) Abstract text: A surgical stent having thereon micro-geometric patterned surface and the method of use for inhibiting smooth muscle cell growth into stent lumen are disclosed. The surgical stent has a generally cylindrical stent frame configured to be implanted into a body lumen, and the stent frame has thereon a micro-geometric patterned surface which includes a multiplicity of microgrooves distributed in a predetermined pattern. Each of the microgrooves has a width in a range of from about 4 to about 40 microns and a depth in a range of from about 4 to about 40 microns. The surgical stent can further include drug wells, and the surgical stent can have a biocompatible chemical compound, such as thrombosis inhibitor or cell growth inhibitor, embedded in the microgrooves or drug wells.
2) The present invention relates to a surgical stent for implantation into a body lumen, such as an artery. More specifically, the present invention relates to a surgical stent which has a micro-geometric patterned surface on the stent frame to inhibit smooth muscle cell growth in the stent lumen and to reduce in-stent restenosis.
3) .....it is apparent that there remains the need of improving the existing drug-eluting stents, and developing alternative designs and methods for inhibiting smooth muscle cell proliferation to reduce in-stent restenosis.
4) With any one of the above-described configurations, the micro-geometric patterned drug eluting stents have double benefit of the chemical inhibition and geometric inhibition on the proliferation of smooth muscle cells. It should be understood that the current drug eluting stent releases its surface coated drug in a short period of time, i.e., in days. Therefore, after the complete release of the coated drug, there is no mechanism to prevent growth of the smooth muscle cell into the stent lumen. With the micro-geometric patterned drug eluting stent of the present invention, the patient not only can be benefited by an immediate chemical inhibition of thrombosis and restenosis caused by the surgical disturbances, the patient can also have a long term benefit of geometric inhibition provided by the micro-geometric patterned surface on the surgical stent. Furthermore, because of the presence of the geometric inhibition mechanism, one can reduce the amount of drug coated on the stent surface, which can reduce potential negative response of the patient to the drug.
5) As described previously, an improved surgical stent which reduces in-stent restenosis has been a long felt need in the medical field. The present invention is the first to provide a geometric inhibition mechanism by incorporating micro-geometric patterns on to the stent surface, thereby inhibiting smooth muscle cell growth into the stent lumen.
>>These guys who financed BLLI earlier this year could be a big help in getting this technology some attention from the big players in this field:
http://www.radiusventures.com/healthcare_industry.asp
Notice that Radius Ventures has previously sold a company to Boston Scientific....and they also have an investment in CONR. Do you think it's a coinsidence that this stent patent application was filed the same day Radius financed BLLI?
But BLLI doesn't do much PR, so you may not hear anything from them about this until there's something real to report about it?
But in the mean time...and at this price....the growth in their core dental implant business could keep them moving up with each quarter's numbers.
...and again, they don't talk about that much either, but they're working hard at increasing market exposure and sales of their dental implants too:
http://www.biolok.com/index.mv?pg=calendar/shows
I can short, but really like the leverage of options....even though it's like playing with a stick of dynamite.
I also worry about the unlimited risk of a short position. Had NFLX come out and said the movie studios were going to allow them to deliver movie content online....it could have gotten ugly....but I really didn't think that was going to happen.
I guess this play wasn't based on the chart much really, but I did see that there was no real big buying volume since NFLX was at $20 in August....and I had a hunch that fundamental might cause the chart to shape up like a head and shoulders.
Well, I made a few blunders, but still made a good call.
I should have waited to but those puts, as I've seen them go as low as $0.50 since I bought them for $1.25.
Lesson learned, if you're betting on a reversal on earnings, wait for the peak of the pre-earnings run.
OT: Zentman, Let me give you a Piece of My Mind. This device will not clean up the Amazon Weirdo, Cry to the Orca.
Float Away With Me for 7 Days in the Arsenic laden waters, then you will know what it really means to be Metal Mike. Afterall, what do you think makes the Funky Weasel so funky?
BTW, nice music in your profile....I enjoyed it :)
If you haven't heard of these guys before, I think you might dig them? I'd suggest watching their "Uninvisible" video at the following link:
http://www.mmw.net/av.jsp
Value Microcappers from Raging Bull, where are they now?
When Bobwins brought us through the desert to I-Hub, he said he'd translate screen names, but I must have missed that post.
I lost track of a few people I had member marked on RB......Deadcat Collector, Isaac Asimov, mobeonadobe, cosmodius, cudawuda, and a few others.
Does anyone know where they are now?
Yep....and the bulls seam to be in control of it too.....those puts I bought for $1.25 went to $1 within an hour of me buying them, ouch!
I realize I'm definately going against the trend with this bet, but I just can't see how it can maintain that frothy valuation. Maybe I should have given myself a bit more time on my options for the fundamentals to play out, but short-term options have the lowest premium....and the best leverage for short-term price fluctuations.....it's a gamble....and I only made a small bet.
I've just seen lots of stocks get hammered on earnings recently....and I can't see how anyone would be excited about the $0.15 EPS for a $28 stock.
Took a gamble and bought some NFLX Oct. $27.50 puts (QNQVY) @ $1.25. NFLX releases earnings next Wednesday and the puts expire next Friday.
Hoping for a doosh below $25.00 by next Friday?
Seams the market is in the mood to consider everything a disapointment. So I'm looking for some naked puts on an over-valued NASDAQ or NYSE issue. But from reviewing the Earnings Calendar on Yahoo!, I'm not finding much of anything that looks extremely overvalued here to me. Many of those stocks have already been hit hard already....and there's not many with P/E's over 20 right now.
EBAY would be the one exception, but I know that would be playing with fire.
Anyone have any good ideas?
Shmolton had a nice doosh on SWKS a few days ago, puts on that would have been nice.
MSGI I edited that sentence out after reading it because it did come across a bit harsh, which wasn't my intention.
I was just surprised how quickly your moved to 100% cash, especially on your VPHM, which I would expect to yield a nice long term gain for those with the patience to hold it through a year....even in a bad market.
I guess we just have a fundamental difference in opinion about how the broader market can affect individual stocks.
But if this conversation seams like deja vous, it’s because this is actually much like the conversation we had on the “Tasty Boosher’s” board in April of this year, when you were all cash then too.
I'm sorry if this discussion will cause you to stop discussing your stock ideas here, you've found some great opportunities.
OT: MSGI, it may be raining here, but the only thing I'm wet with is the venom you just spit at me.
I wasn't insinuating anything, nor was I blaming you for anything. For better or for worse, I never owned VPHM....or any of the "next VPHMs" either. I've actually commended you for your VPHM pick quite a few times in the past....even though I was only a sideliner.
I think most here will agree that I always give credit where credit is due.....and that's actually how quite a few of the regulars here found their way to this message board. I also think you'd have a hard time finding anywhere in my post history where I ever blamed anyone else for my mistakes in trading/investing....I take personal responsibility for my own DD and decisions.
I was really just asking you an investment philosophy question.....that if you really believe in a company's long term potential, why not hold on to some for the long term gains?
Sorry you took it the wrong way and decided to get personal. BTW, who called who a lunatic again? :) Maybe I invited that attack by selecting that obscure literary reference “zen lunatic” as my screen name? But your the first to ever stoop to that level of personal attack. "Zen lunatic" is actually a pretty obscure phrase used by favorite author of mine.....and I don't mind being called a lunatic when kept in that context.
"…see the whole thing is a world full of rucksack wanderers, Dharma Bums refusing to subscribe to the general demand that they consume production and therefore have to work for the privilege of consuming, all that crap they didn't really want anyway such as refrigerators, TV sets, cars,…and general junk you finally always see a week later in the garbage anyway, all of them imprisoned in a system of work, produce, consume, work, produce, consume, I see a vision of a great rucksack revolution thousands or even millions of young Americans wandering around with rucksacks, going up to mountains to pray, making children laugh and old men glad, making young girls happy and old girls happier, all of 'em Zen Lunatics who go about writing poems that happen to appear in their heads for no reason and also by being kind and also by strange unexpected acts keep giving visions of eternal freedom to everybody and to all living creatures." - Jack Kerouac, The Dharma Bums, 1958
The groundhog saw his shadow, so much for the next VPHM.
BLLI: Potential zip code changing patent filed at the USPTO recently:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FP...
The other day I posted why I think BLLI is a good buy just based on their recent growth and expanded sales and marketing efforts for their new Laser Lok implant; but I also mentioned a few "hidden" wild cards in their R&D programs.
This patent application is a real nice example of one of those wild cards. Again, I would caution you that the company won't likely mention their R&D efforts any time soon. But personally, I want to be in BLLI "if and when" they do have something to announce about any of their R&D programs.
But in the meantime, I think they will continue to grow their core dental implant business. As for their sales and marketing effort, they aren't issuing news about these presentations either, but they're really just launching their marketing efforts. I think the fruits of these efforts may begin to show in their numbers some time early next year:
http://www.biolok.com/index.mv?pg=calendar/shows
Len, I almost said something, but decided it wasn't my place since I'm not a board moderator.
But it's that kind of posting that clutters this board and wastes everyone else’s time.
Not to mention, I don't think TVIN meets this boards criteria anymore, it's P/E actually seams quite healthy.
If I were the board moderator, I would consider making some sort of rule about one poster only being able to post 3 times daily about an individual issue.....or something to control these people with diarrhea of the "submit post" button.
I know most of us members don't need such rules, most strive to be succinct in their posts, but paging through something like 10 worthless posts about TVIN yesterday really grated my nerves.
No member mark for midas....that's for sure.
BLLI has had 40% growth in revenue this year, before their recent expansion of their U.S. sales force and the expansion of their overseas distribution network.
These slides from their investor presentation in August in New York contain some more great information:
http://www.sec.gov/Archives/edgar/data/840573/000114420405024754/ex99-2.htm
These are what I considered some of the highlights:
1.) 42% increase in YTD sales without increasing sales force or distributors.
2.) Distribution is expanding to Japan, France, and the UAE now in September '05.
3.) They just began sales in the U.S. last year....and only had 5 U.S. sales people at the time of this presentation....but plan to triple that number for solid geographic coverage.
4.) I also found it interesting to learn that Chip Jones, who BLLI hired as V.P. of Marketing a few months ago, came from Implant Innovations International (3I)....the second largest U.S. Dental Implant company owned by Biomet (NASDAQ: BMET).
5.) They have 3 research studies that will be completed this fall (NYU - Laser Lok, UMDNJ - Laser Lok, and NYU - Bone Gen TR study).
After reviewing that presentation, I think the recent 40% sales growth is just the beginning of what could be a very strong growth trend for this company. They seam to be taking all the necessary steps of building a marketing team, sales force, and clinical data needed to support significant sales growth of their Laser Lok dental implant.....and the launch of their BoneGen TR product next spring
I've been adding BLLI here @ $1.60 really just for the potential organic growth of LaserLok......and BoneGen TR when it is released.
But I also think there's a bit of a wild card to this company with some of their less publicized research. This company is actually doing some very interesting nanotech and biotech research and just not selling it much to investors. Some of this stuff could really generate some market mayhem if they ever decide to publicize it.
This guy on RB finds some great info. on this R&D the company doesn't really publicize. This post summarizes some research they did with Princeton on their Laser microtexturing:
http://ragingbull.lycos.com/mboard/boards.cgi?board=BLLI&read=171
Then pay close attention to this third point "Mechanical/Neural Limb Prosthetic Interface". This stuff is really amazing!!! Bio Lok just might be developing the technology to make The Stepford Wives a reality! Just kidding! But this research could obviously have huge implications for prosthetic limbs if it works....and the Phase II NIH grant is slated to be complete in October:
http://ragingbull.lycos.com/mboard/boards.cgi?board=BLLI&read=154
But as a word od caution, I wouldn't expect to hear anything about this, since the company has not talked about it much in the past. I'm really just expecting nice and steady sales increases in the coming year and beyond.
BLLI: They just launched their Laser Lok dental implant at a conference of periodontists in Denver this weekend:
"This event begining September 25th, a conference attended by about 2,500 doctors and 500 dental students, a good place to launch a new implant."
BLLI had four people at the company's LaserLok presentation at the American Academy of Periodontology Corporate Forum in Denver.
1) John Ricci: one of the inventors of Laser-Lok technology and a faculty member at NYU.
2) Cary Shapoff: dentist, a Director on the American Board of Periodontology, and recent addition to BLLI's Board of Directors.
3) Gabriele Pecora: Scientific Director at ClassImplant (BLLI's Italian distributor), consultant to BLLI, and directed the European clinical trials of the LaserLok implant.
4) Nicholas Elian: NYU faculty member, Director of the NYU Implant International Program at New York University College of Dentistry
http://www.perio.org/meetings/am/forum.htm#3
That presentation also looks like the kick-off of an agressive marketing campaign this fall:
http://www.biolok.com/index.mv?pg=calendar/shows
There was an insider sale on September 15th that raised some questions for me, until I saw who bought the shares:
"Norman Pessin was a principal of Neuberger Berman for more than 2 decades. Small/micro cap investors may be very familiar with one of the stocks in which he is a 5+% shareholder: Metropolitan Health Networks (MDF, formerly MDPA). Norman collectively owns more than 746,000 shares of BLLI."